Description
The National Institute on Drug Abuse (NIDA) is issuing a non‑competitive, sole‑source Notice of Intent to award a purchase order to Novogene Corporation, Inc. for comprehensive human whole‑genome sequencing and bio‑informatics services. The work supports the STAR‑B randomized clinical trial evaluating semaglutide for Alcohol Use Disorder. Novogene will receive biospecimens, perform DNA extraction (if needed), conduct quality control, execute genome‑wide genotyping/sequencing, process raw data, and deliver final datasets with full chain‑of‑custody documentation. The effort must align with the parallel STAR‑T trial at Oklahoma State University to ensure methodological consistency across both studies.
• Scope: DNA extraction, QC, whole‑genome sequencing or genotyping, bio‑informatic processing, data delivery, and documentation.
• Deliverables: Raw sequencing files, processed variant calls, QC reports, sample‑tracking records.
• Value: NAICS size standard $19 M; contract likely under the simplified acquisition threshold.
• Deadline for responses: September 15, 2026 (3:00 PM ED).
• Required: Active SAM registration, UEI, TIN, size‑standard certification.
• Location: Services performed by Novogene (provider) with specimen handling by NIDA.